X
API Suppliers
US DMFs Filed
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
SY-1425 (tamibarotene) is a first-in-class selective retinoic acid receptor alpha (RARα) agonist. It is being evaluated in combination with azacitidine for the treatment of newly diagnosed higher-risk myelodysplastic syndrome (HR-MDS) patients with RARA gene overexpression.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 25, 2024
Details:
The net proceeds will be used to fund the ongoing clinical development of SY-1425 (tamibarotene), a first-in-class selective retinoic acid receptor alpha (RARα) agonist, being developed for myelodysplastic syndromes.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: TD Cowen
Deal Size: $45.0 million Upfront Cash: Undisclosed
Deal Type: Public Offering December 19, 2023
Details:
SELECT-AML-1 is evaluating the safety and efficacy of SY-1425 (tamibarotene) in combination with venetoclax and azacitidine compared to venetoclax and azacitidine in patients patients with acute myeloid leukemia and RARA gene overexpression.
Lead Product(s): Tamibarotene,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 06, 2023
Details:
SY-1425 (tamibarotene), an oral first-inclass selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with azacitidine for the treatment of newly diagnosed HR-MDS patients with RARA gene overexpression.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 26, 2023
Details:
The rates of myelosuppression were comparable to SY-1425 (azacitidine) monotherapy in this population suggesting no added hematologic toxicity from tamibarotene when used in combination with azacitidine. The majority of non-hematologic adverse events (AEs) were low grade.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 12, 2022
Details:
SY-1425, having tamibarotene in combination with venetoclax and azacitidine administered at approved doses showed no evidence of increased toxicity relative to the doublet combination of venetoclax and azacitidine.
Lead Product(s): Tamibarotene,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable December 10, 2022
Details:
The SELECT-AML-1 trial is evaluating SY-1425 (tamibarotene), first-in-class selective retinoic acid receptor alpha (RARα) agonist, in combination with venetoclax and azacitidine in patients with newly diagnosed, unfit acute myeloid leukemia (AML) with RARA gene overexpression.
Lead Product(s): Tamibarotene,Azacitidine,Venetoclax
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 03, 2022
Details:
Tamibarotene (formerly SY-1425) is an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist that we are developing for genomically defined subsets of patients whose disease is characterized by the overexpression of the RARA gene.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oxford Finance
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement September 16, 2022
Details:
SY-1425 (tamibarotene), an oral first-in-class selective retinoic acid receptor alpha (RARα) agonist, is currently being evaluated in combination with azacitidine in the SELECT-MDS-1 Phase 3 trial for RARA-positive patients with newly diagnosed higher-risk MDS (HR-MDS).
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 03, 2022
Details:
Net proceeds are expected to be used to advance Syros’ clinical development pipeline including SY-2101, a novel oral form of arsenic trioxide, business development activities, working capital and other general corporate purposes.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Flagship Pioneering
Deal Size: $130.0 million Upfront Cash: Undisclosed
Deal Type: Private Placement July 05, 2022
Details:
SY-1425 (tamibarotene), selective retinoic acid receptor alpha agonist, is currently being evaluated in combination with azacitidine in the SELECT-MDS-1 Phase 3 trial for RARA-positive patients with newly diagnosed higher-risk MDS.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 02, 2022
Details:
Presentations will include data on SY-1425 and azacitidine combo from a cohort of RARA-positive patients with relapsed or refractory AML and mature data on the combination in newly diagnosed unfit AML patients who are not suitable candidates for standard chemotherapy.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: SY-1425
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
The initial $20 million tranche of this financing extends company's expected cash runway into 2022, beyond key planned clinical data readouts for SY-1425 and SY-5609.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Oxford Finance
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Funding February 13, 2020
Details:
Potential Proof-of-Concept Data for SY-1425 in Combination with Azacitidine in RARA-Positive Relapsed or Refractory AML Patients Expected in Fourth Quarter of 2020.
Lead Product(s): Tamibarotene,Azacitidine
Therapeutic Area: Oncology Product Name: Undisclosed
Highest Development Status: Phase IIProduct Type: Large molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable January 12, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
